Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1297947 | 0.85 | ELANE (0.46) | ELANENPSR1LMNAPOLBCYP2C19 | |
| SCHEMBL1298539 | 0.85 | SIGMAR1 (0.41) | ELANENPSR1MEN1KMT2ATSHR | |
| SCHEMBL1297404 | 0.82 | ELANE (0.38) | ELANENPSR1TSHRCYP2C19TP53 | |
| SCHEMBL1297880 | 0.82 | ELANE (0.38) | ELANENPSR1MEN1KMT2ATSHR | |
| SCHEMBL12104407 | 0.81 | SIGMAR1 (0.40) | ELANENPSR1MEN1KMT2ALMNA | |
| SCHEMBL1298065 | 0.79 | ELANE (0.42) | ELANENPSR1MEN1KMT2ATSHR | |
| SCHEMBL1297405 | 0.77 | ELANE (0.35) | ELANENPSR1CYP2C19 | |
| SCHEMBL1297885 | 0.77 | ELANE (0.35) | ELANENPSR1KMT2ATSHRLMNA | |
| SCHEMBL3372280 | 0.76 | ELANE (0.37) | ELANENPSR1NOTUMTP53 | |
| SCHEMBL3372286 | 0.76 | ACP3 (0.38) | ELANENPSR1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269716-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2011-11-03 | — | — | US | disclosed |
| US-20110269716-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2011-11-03 | — | — | US | disclosed |
| EP-2344454-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | Queensland University Of Technology (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010037172-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269716-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | NQO1, NFE2L2, GPX4 | ELANE 478/4885NPSR1 2259/4885MEN1 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.